Research on Liver Damage Caused by the Treatment of Rheumatoid Arthritis with Novel Biological Agents or Targeted Agents

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2023 Feb 10

PMID 36761903

Authors

Xin Zhao

Chenhao Zhang

Yi An

Zixuan Zhang

Jiahe Zhao

Xinwen Zhang

Yue Yang

Wei Cao

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by polyarticular, symmetric, and aggressive inflammation of the small joints in the hands and feet, resulting in dysfunction. With progress and development in medicine, treatment of RA is constantly evolving, making several drugs available for the treatment of RA. From the nonsteroidal anti-inflammatory drugs (NSAIDs) at the start of illness to glucocorticoids and then to conventional synthetic DMARDs (csDMARDs), biologic DMARDs (bDMARDs), and targeted synthetic DMARDs (tsDMARDs), therapeutic-use drugs for RA have been keeping pace with scientific research. However, various types of drugs have additional side effects when used over the long-term. New and emerging biological and targeted agents have been widely applied in recent years; however, the side effects have not been thoroughly investigated. In this paper, we review the research progress on liver damage caused by novel biological and targeted agents available for RA treatment. The aim is to provide a reference for rational clinical administration of such drugs.

Citing Articles

Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre.

Zhou Z, Fang C, Wang L, Li J, Yang Y, Zhang L RMD Open. 2024; 10(1).

PMID: 38519108 PMC: 10961550. DOI: 10.1136/rmdopen-2023-003985.

Differential Diagnosis: Hepatic Complications in Inborn Errors of Immunity.

Zinser E, Tan K, Kim D, OBrien R, Winstanley A, Yong P J Clin Med. 2023; 12(23).

PMID: 38068532 PMC: 10707526. DOI: 10.3390/jcm12237480.

Associations between Rheumatoid Arthritis and Various Comorbid Conditions in Germany-A Retrospective Cohort Study.

Imanuel C, Sivatheesan S, Koyanagi A, Smith L, Konrad M, Kostev K J Clin Med. 2023; 12(23).

PMID: 38068317 PMC: 10707665. DOI: 10.3390/jcm12237265.

References

Wang J, Zhang X, Geng X, Shi J, Jia X, Dang S . Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases. EClinicalMedicine. 2022; 48:101425. PMC: 9092962. DOI: 10.1016/j.eclinm.2022.101425. View

Kanbori M, Suzuka H, Yajima T, Kishino E, Morishige R, Momohara S . Postmarketing surveillance evaluating the safety and effectiveness of golimumab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2017; 28(1):66-75. DOI: 10.1080/14397595.2017.1325058. View

Taylor P, Keystone E, van der Heijde D, Weinblatt M, Del Carmen Morales L, Reyes Gonzaga J . Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017; 376(7):652-662. DOI: 10.1056/NEJMoa1608345. View

Zhao S, Mysler E, Moots R . Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018; 10(6):433-445. DOI: 10.2217/imt-2017-0155. View

Scott L . Tocilizumab: A Review in Rheumatoid Arthritis. Drugs. 2017; 77(17):1865-1879. PMC: 5736769. DOI: 10.1007/s40265-017-0829-7. View

Nanau R, Neuman M . Safety of anti-tumor necrosis factor therapies in arthritis patients. J Pharm Pharm Sci. 2014; 17(3):324-61. DOI: 10.18433/j3wp4f. View

Kaegi C, Steiner U, Wuest B, Crowley C, Boyman O . Systematic review of safety and efficacy of belimumab in treating immune-mediated disorders. Allergy. 2020; 76(9):2673-2683. DOI: 10.1111/all.14704. View

Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T . Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol. 2021; 36(8):2091-2100. PMC: 8451807. DOI: 10.1111/jgh.15399. View

den Broeder A, de Jong E, Franssen M, Jeurissen M, Flendrie M, Van den Hoogen F . Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice. Ann Rheum Dis. 2005; 65(6):760-2. PMC: 1798177. DOI: 10.1136/ard.2004.033662. View

10.

Furst D, Schiff M, Fleischmann R, Strand V, Birbara C, Compagnone D . Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2004; 30(12):2563-71. View

11.

Zen Y, Yeh M . Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018; 31(6):965-973. DOI: 10.1038/s41379-018-0013-y. View

12.

van Vollenhoven R, Ernestam S, Geborek P, Petersson I, Coster L, Waltbrand E . Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009; 374(9688):459-66. DOI: 10.1016/S0140-6736(09)60944-2. View

13.

Nazir A, Koganti B, Gupta K, Memon M, Aslam Zahid M, Kumar V . Evaluating the Use of Hydroxychloroquine in Treating Patients With Rheumatoid Arthritis. Cureus. 2021; 13(11):e19308. PMC: 8575345. DOI: 10.7759/cureus.19308. View

14.

van de Putte L, Atkins C, Malaise M, Sany J, Russell A, Van Riel P . Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63(5):508-16. PMC: 1755008. DOI: 10.1136/ard.2003.013052. View

15.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

16.

Clarke B, Yates M, Adas M, Bechman K, Galloway J . The safety of JAK-1 inhibitors. Rheumatology (Oxford). 2021; 60(Suppl 2):ii24-ii30. PMC: 8098103. DOI: 10.1093/rheumatology/keaa895. View

17.

Piaserico S, Dapavo P, Conti A, Gisondi P, Russo F . Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature. J Eur Acad Dermatol Venereol. 2017; 31(11):1853-1859. DOI: 10.1111/jdv.14146. View

18.

Amouzougan A, Denarie D, Marotte H, Roblin X, Thomas T . Rheumatoid arthritis treated with tocilizumab in two patients with complicated chronic liver disease with portal hypertension. Joint Bone Spine. 2017; 85(1):115-117. DOI: 10.1016/j.jbspin.2017.07.004. View

19.

Abbasi M, Mousavi M, Jamalzehi S, Alimohammadi R, Bezvan M, Mohammadi H . Strategies toward rheumatoid arthritis therapy; the old and the new. J Cell Physiol. 2018; 234(7):10018-10031. DOI: 10.1002/jcp.27860. View

20.

Chen D, Lin C, Chen H, Tang K . Association of tumor necrosis factor-α inhibitors and liver cirrhosis in patients with rheumatoid arthritis: A nationwide population-based nested case-control study. Int J Rheum Dis. 2022; 25(3):327-334. DOI: 10.1111/1756-185X.14272. View